€6.6M 2-year extension for Ablynx from BI
This article was originally published in Scrip
Executive Summary
Ablynx announced a two-year extension of its five-year research agreement established in September 2007 with Boehringer Ingelheim to discover, develop and commercialise up to ten different Nanobody therapeutics. Ablynx will receive a total of €6.6 million in additional research funding from Boehringer Ingelheim, some of which will be in advance.